Tolerance of a short course of nevirapine, associated with 2 nucleoside analogues, in postexposure prophylaxis of HIV

Journal of Acquired Immune Deficiency Syndromes

Volumn 37, Issue 4, 2004, Pages 1454-1456

  Rey, David ^a,b   Partisani, Marialuisa ^a   Hess Kempf, Georgette ^a   Krantz, Véronique ^a   Priester, Michèle ^a   Cheneau, Christine ^a   Bernard Henry, Claudine ^a   De Mautort, Erik ^a   Decroix, Laetitia ^a   Lang, Jean Marie ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b CISIH   (France)

Author keywords

Hepatotoxicity; HIV; Nevirapine; Postexposure prophylaxis

Indexed keywords

ALANINE AMINOTRANSFERASE; NEVIRAPINE; NUCLEOSIDE DERIVATIVE;

ABDOMINAL PAIN; ARTICLE; ASTHENIA; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MALE; NAUSEA; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; SEROCONVERSION; TREATMENT OUTCOME;

ALANINE TRANSAMINASE; ANTI-HIV AGENTS; DRUG EVALUATION; DRUG THERAPY, COMBINATION; HISTORY, 21ST CENTURY; HIV INFECTIONS; HUMANS; NEVIRAPINE; OCCUPATIONAL EXPOSURE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 10044270792     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000136732.00354.bd     Document Type: Article

References (22)

1. Rabaud C, Bevilacqua S, Beguinot I, et al. Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection. Clin Infect Dis. 2001;32:494-495.
2. Parkin JM, Murphy M, Anderson J, et al. Tolerability and side-effects of post-exposure prophylaxis for HIV infection. Lancet. 2000;355:722-723.
3. Puro V. Post-exposure prophylaxis for HIV infection. Lancet. 2000;355:1556-1557.
4. Montaner JSG, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS trial. JAMA. 1998;279:930-937.
5. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341:1865-1873.
6. Podzamczer D, Ferrer E, Consiglio E, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivtidine in HIV-infected naive patients (the Combine Study). Antivir Ther. 2002;7:81-90.
7. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354:795-802.
8. Anton P, Soriano V, Jimenez-Nacher I, et al. Incidence of rash and discontinuation of nevirapine using two different escalating initial doses. AIDS. 1999;13:524-525.
9. Cattelan AM, Erne E, Saltino A, et al. Severe hepatic failure related to nevirapine treatment. Clin Infect Dis. 1999;29:455-456.
10. Rey D, Partisani M, Krantz V, et al. Prednisolone does not prevent the occurrence of nevirapine-induced rashes. AIDS. 1999;13:2307.
11. Sissoko D, Ajana F, de la Tribonnière X, et al. Manifestations cutanées, hépatiques et hématologiques liées à la névirapine: DRESS syndrome? Presse Med. 2000;29:1041-1042.
12. Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. 2001;15:1261-1268.
13. Kontorinis N, Dieterich D. Hepatotoxicity of antiretroviral therapy. AIDS Rev. 2003;5:36-43.
14. Livrozet JM, Berra N, Ravaux I, et al. The Bill Study: a pilot study assessing the safety of a short-course nevirapine-containing regimen after HIV exposure [abstract P58]. Presented at the 6th International Congress on Drug Therapy in HFV Infection, Glasgow, November 2002.
15. Johnson S, Baraboutis JG. Adverse effects associated with use of nevirapine in HIV postexposure for 2 health care workers [letters]. JAMA. 2000;284:2722-2723.
16. Sha BE, Proia LA, Kessler HA. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers. JAMA. 2000;284:2723.
17. Benn PD, Mercey DE, Brink N, et al. Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1. Lancet. 2001;357:687-688.
18. Johnson S, Chan J, Bennet CL. Hepatotoxicity after prophylaxis with a nevirapine-containing antiretroviral regimen. Ann Intern Med. 2002;137:146-147.
19. Puro V, Soldani F, De Carli G, et al. Drug-induced aminotransferase alterations during antiretroviral HIV post-exposure prophylaxis. AIDS. 2003;17:1988-1990.
20. Patel SM, Johnson S, Belknap SM, et al. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Acquir Immune Defic Syndr. 2004;35:120-125.
21. Lot F, Larsen C, Baum-Parmentier V, et al. Sexual HIV post-exposure prophylaxis (PEP) in France [abstract 226]. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, February 2001.
22. Lot F, Larsen C, Basselier B, et al. Evaluation de la prise en charge thérapeutique des expositions au VIH, Juillet 1999-Décembre 2001. Bulletin Epidémiologique Hebdomadaire. 2002;36:173-175.